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Discovery of a Novel Pathway for an SLE-related Disease 
Complex in the Canine Breed Nova Scotia Duck Tolling Retriever  
Abstract  
The dog is an excellent model to study inherited complex diseases, due to its unique 
population history and haplotype structure. In this thesis, dogs from the breed Nova 
Scotia duck tolling retriever (NSDTR) have been used as a model for defining the 
genetic  factors  controlling  a  systemic  lupus  erythematosus  (SLE)-related  disorder 
called  immune-mediated  rheumatic  disease  (IMRD)  and  a  steroid  responsive 
meningitis-arteritis (SRMA). 
IMRD is characterized by stiffness, mainly after resting, and pain from several joints 
of extremities and/or muscle pain. The majority of the affected dogs show anti-nuclear 
antibody  (ANA)-positivity  that  can  be  divided  either  into  a  speckled  (ANA
S)  or 
homogenous (ANA
H) staining pattern. Dogs affected by SRMA display severe neck 
pain, fever and stiffness and an increased infiltration of immune cells in cerebrospinal 
fluid in the acute phase of disease. SRMA dogs show a negative ANA result.  
We performed a candidate gene study to investigate if dog leukocyte antigen (DLA) 
class II is associated with the canine SLE-related disease. An increased risk for ANA
S 
dogs was observed for a homozygous risk haplotype and a general homozygosity at 
DLA class II gives ANA
H dogs an increased risk for developing disease. 
Genome-wide association mapping identified additional susceptibility loci for the 
SLE-related  disease  on  canine  chromosomes  (CFA)  3,  8,  11,  24  and  32.  Further 
analysis revealed that most ANA
S dogs homozygous for the DLA risk haplotype also 
have the genetic risk factors at CFA 11 and 32. Re-sequencing of the five associated 
regions was performed to identify specific genes and genetic variants involved in the 
disease. 
Expression studies of the candidate genes for ANA
S dogs revealed that the PTPN3 
(CFA 11) gene is downregulated and that DDIT4L and BANK1 (CFA 32) is upregulated 
in dogs with the risk haplotype. The identified genes may be important in T-cells, B-
cells and possibly macrophages. 
This thesis describes the first successful mapping of a complex trait in the dog and 
shows  that  MHC  class  II  together  with  two  other  identified  genetic  risk  factors 
contribute to development of systemic autoimmune disease.  
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1  Introduction 
1.1  The domestic dog as a model 
The exact time and location of the domestication process of the dog from its 
grey wolf ancestors is debated and several efforts have been made to identify 
its origin. Fossil records of dog-like skeletons have been dated back 33,000 
years ago (Ovodov et al., 2011), where mitochondrial DNA (deoxyribonucleic 
acid)  analysis  and  single  nucleotide  polymorphism  (SNP)  data  dates  the 
domestication process ~15,000 years back (Larson et al., 2012; Pang et al., 
2009;  Savolainen  et  al.,  2002;  Vila  et  al.,  1997).  How  the  dog  was 
domesticated is also unclear (Niskanen et al., 2013; Ding et al., 2012). One 
hypothesis is that human selected wolfs to fulfill their purposes (e.g. a friendly 
behavior  and  good  hunting  skills).  Both  behavioral  and  morphological 
differences occur between dog and wolf and efforts have been made to identify 
genetic  differences  responsible  for  such  traits.  A  genome-wide  association 
study  (GWAS)  performed  in  several  dog  breeds  and  12  wolfs  distributed 
world-wide was performed and identified strong selection for genes important 
in brain function, starch digestion and fat metabolism, which may underlie an 
adaptation to a starch rich diet (Axelsson et al., 2013).  
During  the  dog  domestication  process  a  first  bottleneck  occurred, 
decreasing the genetic pool, since it is believed that only a limited number of 
wolfs  were  founders  of  the  dog  population.  A  second  bottleneck  occurred 
recently, during breed creation, creating around 400 different breeds worldwide 
(Fogle et al., 2000). Most breeds were shaped less than 200 years ago. The dog 
has been selected and bred for its unique characteristics, such as morphological 
traits  (skull  shape,  body  size,  coat  color  etc.)  as  well  as  behavioral  traits 
(hunting,  herding,  guarding,  tolling  and  retrieving)  creating  a  unique 
population  structure,  with  each  breed  arising  from  a  limited  number  of 
founders. This has resulted in a unique population structure within the dog.   12 
Short  ancestral  haplotype  blocks  are  shared  between  breeds,  from  the 
domestication of the wolf population and long haplotype blocks occur within a 
dog breed (Karlsson & Lindblad-Toh, 2008; Lindblad-Toh et al., 2005; Sutter 
et al., 2004). 
Many breeds share recent common ancestors meaning that they also likely 
share  common  disease-causing  alleles,  offering  a  unique  opportunity  for 
genetic  studies  (Parker  et  al.,  2004).  Dogs  suffer  from  many  of  the  same 
diseases  as  humans,  such  as  cancer,  epilepsy,  heart  diseases,  allergies  and 
autoimmune diseases. The different diseases have in both dog and human a 
similar frequency and the same genetic factors are often involved (Karlsson & 
Lindblad-Toh, 2008).  
Specific  diseases  occur  in  certain  breeds,  suggesting  a  common  genetic 
component.  The  genetic  variation  is  limited  within  breeds  compared  to 
between breeds, which gives canine studies unique opportunities to understand 
the  genetic  mechanisms  of  natural  variation  in  mammals,  including  disease 
susceptibility (Ostrander, 2012; Shearin & Ostrander, 2010). 
 
There are several advantages for using the dog as a genetic model: 
￘  Similarities between the canine and human genome 
￘  Each breed represents a closed breeding pool 
￘  Homogeneity within a dog breed 
￘  Trait-causing mutations are identical-by-descent (IBD) within a breed 
￘  Same spontaneously occurring diseases as in humans 
￘  Human and dog share environment 
￘  Medical records and pedigrees accessible 
￘  Easier to identify associated loci of interest than in humans  
￘  Less cases and controls are needed 
 
Challenges when using the dog as a model include:  
￘  Difficult to obtain sufficient number of samples needed 
￘  Population stratification  
￘  High  linkage  disequilibrium  (LD)  can  make  it  difficult  to  get  from 
associated locus to mutation 
￘  Difficult to identify additional breeds that share the same phenotype for 
narrowing down associated regions 
1.1.1  Nova Scotia duck tolling retriever 
In this thesis, dogs from the breed Nova Scotia duck tolling retriever (NSDTR) 
have been used as a model for understanding the genetic factors controlling 
complex  immune-mediated  disease,  as  this  breed  has  been  shown  to  be   13 
overrepresented  to  develop  such  diseases.  The  history  of  the  NSDTR  is 
interesting and important to remark since it influences the genetic studies and 
its interpretations of the results presented in this thesis. 
The NSDTR is bred for its special behavior– tolling. A tolling dog plays, 
runs  and  jumps  around  the  shore,  sometimes  disappearing  for  creating  a 
curiosity from birds, luring them to swim closer to the shore to appear within 
shooting distance to the hunter. After the hunter shoots the bird, the dogs are 
sent out to retrieve them (Figure 1) (Strang & MacMillan, 1996). 
 
 
 
Figure  1.  Pancho,  a  Nova  Scotia  duck  tolling  retriever 
(NSDTR).  These  dogs  are  bred  for  their  fox-like 
appearance that is used to attract and retrieve birds for the 
hunter (photo: R. Meijer).  
 
 
 
 
The origin of the NSDTR is slightly unclear and several speculations occur. 
Both the appearance  and  their  special  behavior  (tolling)  have  been  used  in 
attempts to trace the breed’s background. 
The  NSDTR  as  a  breed  may  be  traced  to  Europe  before  the  sixteenth 
century where dogs with similar behaviors and appearance were described. It is 
believed that the NSDTR derives from the Dutch breed Kooikerhondje. These 
dogs  were  used  by  the  Dutch  people  to  lure  ducks  into  traps  –  a  similar 
behavior as the NSDTR, but without the retrieving qualities. From Holland 
these dogs were imported to England and France for their fox-like resemblance 
to lure ducks into the hunters nests. During the French colonization of Acadia 
(nowadays Nova Scotia, Canada), it is hypothesized that the French people 
brought these dogs over when they established their first permanent settlement. 
The NSDTR was developed in the Yarmouth region of Nova Scotia and first 
described in the early 1800s. At that time it was known as Little River Duck 
Dog or the Yarmouth Toller (Strang & MacMillan, 1996).  
Little is known of what happened during the coming 200 years. But crosses 
with different breeds have been proposed for the development of the modern 
NSDTR  breed.  Potential  crosses  with  Labrador  retriever,  Chesapeake  Bay 
retriever, Brittany spaniel, Golden retriever and perhaps some small farm collie   14 
have been suggested (Perrin, 2012; Strang & MacMillan, 1996). It is important 
to understand the background of the NSDTR to ease the genetic studies and 
break down the high degree of LD within a dog breed by using related breeds.  
An important part of the history affecting the development of NSDTR is 
that canine distemper virus (CDV) outbreaks were reported to occur twice in 
history;  in  1908  and  1912.  This  reduced  the  population  size  to  only  a few 
individuals. A theory is that the predisposition to autoimmune diseases in the 
modern NSDTR may be a result of the early NSDTRs ability to survive these 
outbreaks of CDV (Strang & MacMillan, 1996). A highly efficient immune 
response towards a virus or other pathogens can lead to that the body starts to 
react against a self antigen and treats it as foreign and initiates an autoimmune 
reaction  directed  towards  the  self  antigen  or  cells  expressing  the  antigen. 
NSDTRs  are  reported  to  have  an  increased  incidence  of  a  systemic  lupus 
erythematosus  (SLE)-related  disease  (immune-mediated  rheumatic  disease 
(IMRD))  (Hansson-Hamlin  &  Lilliehook,  2009),  steroid-responsive 
meningitis-arteritis  (SRMA)  (Anfinsen  et  al.,  2008;  Redman,  2002)  and 
Addison’s disease (Hughes et al., 2010; Hughes et al., 2007; Burton et al., 
1997). In our Scandinavian study population we most often see IMRD and 
SRMA  (Hansson-Hamlin  &  Lilliehook,  2009),  whereas  in  USA,  Addison’s 
disease seems to be more common. One possible explanation to this is that 
different risk alleles segregate in these populations. Sometimes NSDTRs are 
also affected by hypothyroidism (unpublished observation).  
The first 15 NSDTR dogs were registered in the Canadian Kennel Club in 
1945, but these dogs were still a quite well kept secret of southwestern Nova 
Scotia.  Breeding  problems  almost  led  to  extinction  of  the  population  once 
again in the mid 20
th century. Breeder enthusiasts saved the breed by using 13 
dogs that are the founders of the current NSDTR population. The first NSDTR 
was imported to Sweden in 1984 (Strang & MacMillan, 1996). It is currently a 
popular  breed  and  around  400  dogs  are  registered  in  Sweden  each  year 
(Tollarklubben, 2007). 
1.1.2  Autoimmune and immune-mediated diseases 
Developments of autoimmune and immune-mediated diseases are dependent 
on both genetic and environmental risk factors. Combined, these factors will 
affect the overall reactivity of the immune system and control which antigen to 
be  targeted.  Autoimmune  diseases  are  classified  into  two  groups,  organ-
specific and systemic autoimmune diseases. This is dependent on where the 
target  antigen  is  expressed.  In  organ-specific  autoimmune  diseases  the 
autoantigen only occurs in a certain tissue or cell type, whereas in systemic   15 
autoimmune disease the response is directed against autoantigens expressed 
throughout the body. 
Autoimmune diseases occur in up to 3–5% in the general human population 
(Jacobson  et  al.,  1997)  and  most  organs  in  the  body  have  an  autoimmune 
disease connected (Marrack et al., 2001). 
Similar  or  sometimes  the  same  genes  are  often  involved  in  several 
autoimmune diseases. SLE may exemplify this, where the same genes or gene 
families are reported to be associated with other systemic rheumatic diseases or 
sometimes even organ-specific autoimmune diseases. One hypothesis is that 
there are genetic risk factors that are common to many autoimmune diseases 
and others that are specific for each disease (Shamim & Miller, 2000).  
Autoimmune  diseases can  be  mediated  by  T-cells,  where  both  CD4
+  T-
helper cells and sometimes CD8
+ T-killer cells have an important role and the 
organ damage is mediated by T-cells (e.g. type I diabetes) (Homann & von 
Herrath, 2004). In SLE, damage is initiated by autoantibodies and CD4
+ T-
helper cells and an increased level of antibodies are observed. These antibodies 
form immune complexes and can cause glomerulonephritis (Kotzin, 1996). 
The  dog  share  many  autoimmune  and  immune-mediated  diseases  with 
humans, such as SLE-related disease vs. SLE in humans (the disease studied in 
this thesis). A few of them are described below (Table 1). 
Table 1. Examples of similar autoimmune or immune-mediated diseases that occur spontaneously 
in the dog and human. 
Dog disease  Human disease 
Canine diabetes mellitus   Latent autoimmune diabetes of adults 
Hypoadrenocorticism  Addison’s disease 
Primary immune-mediated haemolytic 
anaemia 
Autoimmune haemolytic anaemia 
Canine systemic lupus erythematosus 
(SLE)/ SLE-related rheumatic disease 
(ANA-positive) 
Systemic lupus erythematosus (SLE)/ SLE-related 
rheumatic disease (ANA-positive) 
Canine rheumatoid arthritis  Rheumatoid arthritis 
Symmetrical lupoid onychodystrophy  Several keratin disorders  
Canine lymphocytic thyroiditis   Hashimoto’s thyroiditis 
Necrotizing meningoencephalitis  Acute forms of multiple sclerosis 
Uveodermatologic (UV) syndrome  Vogt – Koyanagi – Harada syndrome 
 
1.1.3  SLE and SLE-related disease complex 
In humans, SLE is a heterogeneous autoimmune disease with a wide range of 
clinical signs. The classification is based on 11 different criteria defined by the   16 
American  College  of  Rheumatology  (ACR)  (Hochberg,  1997;  Tan  et  al., 
1982),  ranging  from  mild  to  severe  symptoms.  Four  groups  include 
dermatological signs (such as butterfly rash, discoid rash, photosensitivity and 
oral ulcerations) and another four groups include systemic criteria (arthritis, 
serositis,  renal  and  neurological  disorders).  Laboratory  findings  include 
haematologic disorders and immunologic disorders (such as groups based on 
ANA-positivity).  Four  (or  more)  of  the  criteria  are  required  for  an  SLE 
diagnosis (Hochberg, 1997; Tan et al., 1982).  
Attempts to create a similar list of criteria for SLE in dogs have been made, 
but no consistent list exists. Therefore it is often more difficult to diagnose 
canine SLE. Moreover, ANA positive dogs usually show clinical signs with 
focus on stiffness and musculoskeletal signs and more seldom impact of other 
organs.  Thus,  the  disease  in  these  dogs  is  often  called  SLE-related  disease 
(Hansson et al., 1996).  
NSDTRs  have  been  shown  to  be  overrepresented  to  develop  immune-
mediated  disease  complexes;  mainly  the  SLE-related  disorder  IMRD  and 
SRMA. These disorders have been genetically investigated in this thesis. 
When the genetic studies started in 2007 it was unclear if these diseases had 
a correlation or if they were separate disorders. One of the aims of this project 
was to define whether unique or combined genetic risk factors occur within the 
disease complex/complexes. 
IMRD is characterized by stiffness, mainly after being inactive, pain from 
several  joints  of  extremities  and  muscle  pain.  Sometimes  fever  and  skin 
problems are observed, while concurrent liver and kidney changes are rare. 
Initial  signs  of  disease  are  usually  shown  between  2-6  years  of  age.  Most 
affected dogs have high serum concentrations of anti-nuclear antibodies (ANA) 
and  are  therefore  termed  ANA-positive.  Treatment  usually  involves 
corticosteroids and the results may differ. For some dogs, treatment eventually 
may  be  withdrawn  while  in  a  minority  of  cases  corticosteroid-treatment  is 
insufficient. Most dogs need a lifelong corticosteroid-treatment with a low dose 
(Hansson-Hamlin & Lilliehook, 2009). During 2010-2011, 16 NSDTR newly 
diagnosed dogs with an ANA-positive phenotype were reported to us at the 
University  Animal  Hospital,  Swedish  University  of  Agricultural  Sciences 
(SLU), Uppsala, Sweden. ANA tests may be performed at other clinics, but the 
majority of the cases are sent to the clinic at SLU. Around 400 NSDTRs are 
registered each year, suggesting an incidence of at least 2% in the Swedish 
population.  However,  a  longer  time  period  is  needed  to  obtain  conclusive 
results. The incidence of 2% is most likely an underestimate, but it gives an 
indication  of  how  common  this  disease  is  in  the  Scandinavian  NSDTR 
population. In 2003, another study estimated the prevalence of IMRD in the   17 
Swedish population by sending out a health form to all dogs born 1998. 35% of 
the dogowner responded and the prevalence of IMRD was estimated to 2.3% 
(Tollarklubben, 2007). 
Dogs affected by SRMA display severe neck pain, fever and stiffness. The 
age  of  onset  is  usually  between  4-19  months.  An  increased  infiltration  of 
immune cells can be seen during investigation of cerebrospinal fluid in the 
acute  phase  of  disease.  SRMA  dogs  always  show  a  negative  ANA  result. 
Corticosteroids are often recommended for these dogs as well, usually with a 
remarkably good response within one or two days (Anfinsen et al., 2008). In 
the study from 1998, the prevalence of SRMA in Sweden was predicted to 
3.0% (Tollarklubben, 2007). 
Our hypothesis was that IMRD and SRMA represent two separate disorders 
with  some  common  but  mostly  distinct  genetic  risk  factors.  In  our  genetic 
studies  we  therefore  considered  the  IMRD  and  SRMA  as  two  separate 
disorders but also analyzed them for shared genetic risk factors. Clinically the 
phenotypes look very different, although they both seem to have an immune-
mediated background. 
1.1.4  Antinuclear antibodies (ANA) 
During  an  immune  response  against  extracellular  pathogens,  professional 
antigen-presenting cells process the antigens and present peptides on major 
histocompatibility complex (MHC) class II molecules to the T-cell receptor 
(TCR)  on  CD4
+  T  helper  cells.  After  such  an  antigen-presentation  of  the 
extracellular  antigens,  antibodies  are  produced  by  B-lymphocytes.  In 
autoimmune diseases autoantibodies are produced against self-antigens. Such 
autoantibodies may be used as a hallmark for several autoimmune diseases in 
both humans and domestic animals.  
ANA are autoantibodies directed against different nuclear antigens and are 
found in patients with certain systemic rheumatic diseases, including SLE, in 
both humans and dogs (Kavanaugh et al., 2000; Hansson et al., 1996). ANA 
can  be  subdivided  according  to  their  specificity.  In  humans,  certain 
autoantibodies have been shown to produce distinct patterns of staining when 
they  react  with  specific  antigens  e.g.  dsDNA  (double-stranded  DNA) 
(Kavanaugh  &  Solomon,  2002),  histone  (Burlingame  &  Rubin,  1991),  Sm 
(Smith  antigen,  a  complex  of  ribonucleic  acid  (RNA)  and  protein)  (Tan  & 
Kunkel, 1966), RNP (ribonucleoprotein, react with proteins present in the U1 
snRNP complex) (Benito-Garcia et al., 2004), SSA/Ro (two proteins, Ro60 
localized to the nucleus and nucleolus and Ro52 localized in the cytoplasm) 
(Chan  et  al.,  1991)  and  SSB/La  (RNA-binding  protein  important  in 
transcription mediated by RNA polymerase III) (Chambers et al., 1988).   18 
In  general,  anti-dsDNA  and  -histone  antibodies  produce  a  homogenous 
staining  pattern  (ANA
H),  whereas  anti-Sm,  -RNP,  -SSB/La  and  -SSA/Ro 
produces  a  speckled  pattern  (ANA
S).  ANA
H  is  associated  with  antibodies 
directed  against  chromosomal  antigens,  whereas  ANA
S  is  associated  with 
antibodies  against  non-chromosomal  antigens.  Moreover,  autoantibodies 
directed towards certain specific antigens are in humans correlated to different 
specific disorders and some specific autoantibodies occur in several disorders 
(Tan, 1989). A specific marker for SLE is Anti-Smith (Anti-Sm) antibodies 
and anti-dsDNA (Kavanaugh & Solomon, 2002; Tan & Kunkel, 1966). 
When conducting the immunofluorescence (IIF) ANA-test on canine sera, 
these  patients  usually  display  either  a  homogenous  or  a  speckled  staining 
pattern. The specific autoantigens may be difficult to determine with traditional 
methods in SLE-related disease in dogs (Hansson & Karlsson-Parra, 1999). 
Anti-RNP and anti-dsDNA antibodies have been reported in several dog breeds 
displaying ANA reactivity (Lin et al., 2006; Monier et al., 1992). The specific 
ANA-reactivity in IIF ANA-positive NSDTR dogs is so far unknown.  
Dogs from several different breeds have been reported to be affected by an 
SLE-like disease (including a positive ANA-test) such as the German shepherd 
(Hansson et al., 1996; Thoren-Tolling & Ryden, 1991). 
A study conducted using dogs from 27 different breeds affected by SLE or 
SLE-related disease showed that 25% had a homogenous (ANA
H) staining and 
had clinical signs from multiple organs. The other 75% showed a speckled 
pattern (ANA
S) with musculoskeletal disorders, fatigue and fever (Hansson-
Hamlin et al., 2006)(Figure 2). Similar results were obtained in a study using 
33  NSDTRs  where  39%  showed  a  homogenous  staining  pattern  and  61% 
showed a speckled pattern (Hansson-Hamlin & Lilliehook, 2009). 
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Figure 2. ANA-staining patterns in dogs shown by the indirect immunofluorescence (IIF) ANA-
test.  Homogenous  staining  shows  reactivity  in  the  chromosomal  regions  whereas  speckled 
pattern  lack  chromosomal  activity.  (Modified  with  permission  from  (Hansson-Hamlin  et  al., 
(2006))  
Besides SLE and SLE-related diseases, a positive ANA-test in the dog has also 
been observed in a few other autoimmune diseases. Gordon setter dogs with 
symmetrical  lupoid  onychodystrophy  (Ovrebo  Bohnhorst  et  al.,  2001)  and 
beagles  with  autoimmune  thyroiditis  (Vajner,  1997)  may  display  ANA-
positivity (30-35% vs. 10%).  
1.1.5  Similarities to human SLE  
Some  symptoms  are  shared  between  human  SLE  and  SLE-related  disease 
complex in the dog, such as arthritis and a positive ANA test (Hansson-Hamlin 
& Lilliehook, 2009) (Table 2). Other symptoms that occur in both species are 
skin symptoms, fever, and liver problems. Kidney problem is rarely seen in the 
dog but do occur. MHC class II has also been identified as a genetic risk factor 
in both humans and the dog (Paper I and III) (Fernando et al., 2008).  
Table 2. Shared clinical symptoms between human SLE and the SLE-related disease affecting 
NSDTR. 
  ANA +  Joint  Skin  Fever  Liver  Kidney  MHC class II 
Dog  Yes  Yes  Sometimes  Sometimes  Sometimes  Rarely  Yes 
Human  Yes  Yes  Yes  Yes  Yes  Yes  Yes 
 
Women  in  childbearing  age  are  more  often  affected  than  men  (80-90%) 
(Danchenko et al., 2006), which is a difference compared to the SLE-related 
disease  in  NSDTR  dogs,  where  a  similar  distribution  is  observed  between 
gender (Hansson-Hamlin & Lilliehook, 2009). In general, there are no gender   20 
differences observed in autoimmune diseases in the dog and the reason why is 
unknown. 
Both genetic components and environmental factors are involved as risk 
factors for development of  the disease. More than 40 different genetic risk 
factors have been identified and confirmed in humans, many of importance for 
B-  and  T-cell  activation,  type  I  interferon,  immune-complexes and toll-like 
receptors (Cui et al., 2013).  
Genetic  data  identified  in  the  SLE-related  disease  and  presented  in  this 
thesis  implicates  the  importance  of  a  T  cell-specific  pathway  (Paper  I-III). 
Several genes important for T cell-specific signaling and activation have also 
been identified in humans with SLE, including the human leukocyte antigen 
(HLA)  class  II  region,  PTPN22,  TNFSF4,  STAT4  and  CD44  (Table  3). 
Interestingly,  all  of  these  genes  have  also  been  denoted  as  risk  factors  in 
several other autoimmune diseases (Cui et al., 2013). 
Table 3. Genetic risk factors associated with T-cell signaling or activation identified in human 
SLE patients. 
Chromosome  Gene  SNP type  Reference 
1p13  PTPN22  exonic  (Criswell et al., 2005) 
1q25.1  TNFSF4  intergenic  (Cunninghame Graham et al., 2008) 
2q32.3  STAT4  intron  (Remmers et al., 2007) 
6p21.32-33  HLA-DQA1, HLA-DQA2  intergenic  (Chung et al., 2011) 
6p21.32-33  HLA-DR3  intron  (Chung et al., 2011) 
6p21.32-33  HLA-DRB1  intergenic  (Gateva et al., 2009; Han et al., 2009) 
11p13  CD44  intergenic  (Lessard et al., 2011) 
 
PTPN22  (protein  tyrosine  phosphatase,  non-receptor  type  22)  is  associated 
with  the  inhibition  of  T-cell  receptor  and  development  of  autoantibody 
production  (Criswell  et  al.,  2005).  Tumor  necrosis  factor  superfamily  4 
(TNFSF4)  is  a  co-stimulatory  molecule  for  CD4
+  T  helper  cells  and  is 
expressed on activated antigen-presenting cells. TNFSF4 show correlation to 
increased expression in patients with SLE (Cunninghame Graham et al., 2008). 
STAT4 (Signal transducer and activator of transcription 4) transmits signals 
from cytokines, type I interferons and interleukins (-12 and -23) and stimulates 
transcription of genes important for T-cell differentiation (Th1) (Nishikomori 
et  al.,  2002).  CD44  is  a  cell-surface  glycoprotein  and  is  important  in 
lymphocyte activation. T-cells from SLE patients have shown overexpressed 
CD44 (Li et al., 2007). The HLA class II region is the strongest genetic risk 
factor for SLE (Chung et al., 2011; Gateva et al., 2009; Han et al., 2009) and 
has  been  associated  to  a  number  of  autoimmune  diseases  in  humans  like   21 
multiple sclerosis, rheumatoid arthritis and type I diabetes (Fernando et al., 
2008).  
Most of the associated SNPs in the studies described above occur in non-
coding regions. There are infrequently SNPs occurring in regions with a known 
function, such as in coding region, splice site mutation or 3’ or 5’ untranslated 
regions  (UTR).  The  mutations  are  more  likely  to  be  important  for  gene 
regulation, transcription factor binding sites, enhancers or promoters. 
The genes identified as risk factors for human SLE are only explaining a 
small part of the inheritance of the disease, only showing odds ratios (OR) with 
a median effect (~1.25) (Manolio et al., 2009; Pawitan et al., 2009). A higher 
concordance rate in monozygotic twins than in dizygotic twins or siblings has 
been observed, but lack complete concordance (Alarcon-Segovia et al., 2005). 
The  low  OR  and  missing  heritability  suggests  an  important  role  for  the 
environmental factors in the pathogenesis of SLE.  
There is also extensive clinical heterogeneity of SLE. By using the SLE-
related  disease  in  NSDTR  as  a  model,  we  may  discover  new  genes  and 
pathways  involved  in  the  development  of  SLE  and  provide  improved 
subdivision of patients dependent on the same immunological subgroup. 
1.2  Mapping the first complex trait in the dog 
In 1989, DNA sequencing identified the first genetic variant for an inherited 
canine disorder, haemophilia B. A single missense mutation was identified in 
the canine Factor IX gene, which encodes a glycoprotein that is required for 
blood coagulation (Evans et al., 1989). The rapid developments of high-density 
SNP  arrays,  nucleotide  sequencing  technologies  and  the  sequencing  of 
genomes have made it easier and possible to identify loci also for a complex 
trait.  
The  results  presented  in  this  thesis  describe  the  first  successful  genetic 
mapping of a complex trait in the domestic dog. Previously, genetic mapping 
of several monogenic diseases or traits have been described in the dog such as 
the gene encoding the sleep disorder narcolepsy (Lin et al., 1999). Two proof-
of-principle GWAS were previously performed on monogenic traits, the white 
spotting  locus  and  the  hair  ridge  in  Rhodesian  ridgebacks  (Karlsson  et  al., 
2007) predisposing dermoid sinus (Salmon Hillbertz et al., 2007). The results 
in this thesis have used a combination of three different strategies, a candidate 
gene approach to investigate the dog MHC class II, a genome-wide association 
mapping  (GWAM)  to  unbiased  search  for  risk  loci  and  next  generation 
sequencing technologies to identify genetic variants important for mechanisms 
involved  in  disease  development.  The  sequencing  of  the  dog  genome  and   22 
techniques used to identify associated regions are described in the following 
sections.  
1.2.1  The dog genome and genetic variation 
The report of a draft sequence of the human genome in 2001 (Lander et al., 
2001; Venter et al., 2001) opened up new doors to study the genome in depth. 
In 2005, the dog genome sequence of a female boxer, Tasha, was published, 
covering 99% of the genome (Lindblad-Toh et al., 2005). This dog was chosen 
based  on  tests  for  a  low  rate  of  heterozygosity,  which  makes  it  easier  to 
assembly the sequences and generate a better quality of the genome sequence. 
The dog has 38 autosomal chromosomes and the sex chromosomes X and 
Y. The genome structure is 2.4 Gb in size and contains 20,657 protein-coding 
genes with RNA-sequencing evidence (M. Grabherr, personal communication). 
The dog genome is smaller than the human and mouse genomes, partly because 
of a lower amount of some repeat insertions including endogenous retroviruses 
in  the  dog  genome  (Barrio  et  al.,  2011).  The  mechanisms  underlying  this 
difference are unknown but could be caused by a combination of canids being 
more  efficient  in  purging  repetitive  DNA  sequences  and  having  a  more 
restricted number of canid-specific infectious retroviruses. Overall, 94% of the 
dog  genome  is  in  conserved  synteny  to  the  human  and  mouse  genomes 
(Lindblad-Toh et al., 2005). Some genes that only appear in the dog genome 
are genes encoding G protein-coupled olfactory receptors. This is a result of 
positive selection for duplications in this gene family leading to canid-specific 
expansion of such genes. 
In  parallel  to  the  sequencing  of  the  dog  genome,  SNP  discovery  was 
performed using dogs from 11 different breeds, which identified 2.5 million 
SNPs (on average 1 SNP per 1,000 base pair (bp)) (Lindblad-Toh et al., 2005). 
Types  of  variation  that  occur  within  the  genome  are  SNPs,  insertions  or 
deletions (InDels) and other structural variations such as copy number variants 
(CNV) - deleting or duplicating a large region of the DNA and inversions - a 
chromosome rearrangement. 
Within a dog breed LD is extensive with haplotypes extending 0.5-1.0 mega 
bases (Mb) in size, but between breeds LD is only around 10 kilo bases (Kb). 
Some breeds share longer haplotypes within the shorter ones, suggesting that 
shared genetic risk factors can occur, due to the two bottlenecks described in 
chapter 1.1 (Karlsson & Lindblad-Toh, 2008; Sutter et al., 2004).  
1.2.2  Candidate gene approach 
The  genes  studied  in  a  candidate  gene  approach  are  chosen  based  on  a 
hypothesis-biased search. The genes can be located in a place in the genome   23 
previously associated with linkage studies, the genes may be involved in the 
same pathway as other genes implicated to be important for the disease, genes 
may be expressed in cells or tissues important and relevant for the disease or 
associated in other model organisms with same/similar disease.  
Most  commonly,  SNPs  are  genotyped  to  tag  associated  haplotypes,  but 
sequencing can also be used for part of a gene, the entire gene, promoters and 
conserved  elements.  The  candidate  gene  approach  is  useful,  because  less 
markers and samples are needed to generate sufficient statistical power and less 
multiple testing corrections are required. It is also of lower cost than more 
high-throughput methods.  
The candidate gene approach was used for Paper I and III for sequencing 
the polymorphic exon 2 of MHC class II, because it is known as an important 
genetic risk factor in SLE and other autoimmune diseases in humans, mice and 
other mammals. The biological function of MHC class II molecules as antigen-
presenting molecules is also of relevance for the disease development. 
1.2.3  Genome-wide association mapping  
Genome-wide association mapping (GWAM) was used in Paper II to perform 
an unbiased scan of the entire genome in controls and cases affected by the 
SLE-related disease in NSDTR. The dog-sequencing project (Lindblad-Toh et 
al.,  2005)  identified  a  large  number  of  SNPs  used  to  create  canine  SNP 
genotyping  arrays  used  for  GWAM.  The  first  SNP  array  contained  27,000 
markers (Karlsson et al., 2007). Subsequently, a 22K array (that was used in 
Paper II in this thesis) and 50K were developed and finally the high density 
173K genotyping array (Vaysse et al., 2011) is now available.  
When performing a GWAS, the entire genome is scanned in all individuals 
from a case-control population in an attempt to find regions where the affected 
individuals  are  genetically  identical  and  differ  from  the  healthy  controls, 
defining  an  associated  haplotype.  The  associations  can  either  be  a  single 
marker  in  LD  with  the  causative  mutation,  an  associated  haplotype  or  the 
actual causative mutation. In dogs, like other domestic animals, this approach 
is  particularly  powerful  since  dog  breed  creation  occurred  recently,  few 
recombination  events  have  occurred  and  long  haplotype  blocks  can  be 
identified  that  potentially  share  the  trait  of  interest,  an  IBD  region.  The 
advantage of using the dog is that fewer markers, compared to e.g. humans are 
needed. It has been estimated that 10,000 to 15,000 SNPs are sufficient in the 
dog (Lindblad-Toh et al., 2005; Sutter et al., 2004) compared to 300,000 to 
1,000,000 in humans (Gabriel et al., 2002).  
Fewer samples are also needed in the dog compared to humans. It has been 
estimated that to map a Mendelian recessive trait in the dog, only 20 cases and   24 
20 controls are needed and that for a complex disease an allele conferring a 5-
fold increased risk requires 100 cases and 100 controls to have 98% chance of 
being  detected  (Karlsson  &  Lindblad-Toh,  2008;  Karlsson  et  al.,  2007; 
Lindblad-Toh et al., 2005). Compared to humans, larger study populations are 
needed  e.g.  6,000  cases  and  6,000  controls  would  generate  94%  power  to 
detect disease susceptibility variants with an odds ratio of 1.3 and minor allele 
frequency (MAF) of 0.1 (Wang et al., 2005). 
The study population used is a case/control cohort based on strict inclusion 
and exclusion criteria. In the dog it can be easier to collect random unrelated 
cases  and  controls  than  to  collect  complete  families  (as  previously  used  in 
linkage  studies).  To  avoid  stratification  it  is  important  to  use  unrelated 
individuals from the same population structure, otherwise false positives may 
occur due to the heterogeneity effect.  
We used a 2-stage mapping strategy. In the first stage, GWAM, we used 
one breed with the disease or trait of interest. A homogenous study population 
is required to avoid false positives. The hypothesis is that the mutation arose 
before  breed-creation.  Allele  frequencies  between  cases  and  controls  are 
compared  and  long  (around  1Mb)  regions  are  identified.  To  narrow  down 
associated regions the second stage is applied, fine-mapping. More SNPs are 
added to the associated regions and preferably samples from a related breed 
sharing the same disease or trait of interest. Since haplotypes are short (around 
10  Kb)  across  breeds  the  associated  haplotype  can  effectively  be  narrowed 
down (Karlsson & Lindblad-Toh, 2008; Karlsson et al., 2007).  
Many studies have been successfully performed to map monogenic traits 
and in this thesis we present the first complex trait successfully mapped (Paper 
II). 
1.3  The role of MHC class II in canine autoimmune diseases 
Major histocompatibility complex (MHC) was described in the 1930s by Peter 
A. Gorer (Gorer, 1937). The organization of the region is highly conserved 
between species and consists of three classes: 
 
￘  MHC  class  I:  expressed  by  all  nucleated  cells  except  neurons,  present 
intracellular antigens and mediates CD8
+ T killer cells to destroy infected 
cells. 
￘  MHC class II: expressed by professional antigen-presenting cells, presents 
extracellular antigens to CD4
+ T helper cells, which leads to activation of 
B-cells to produce antibodies to the specific antigen.   25 
￘  MHC class III: encode genes in the complement system (innate immune 
system). 
 
The data presented in this thesis have focused on the polymorphic genes of the 
dog MHC class II because of their well-established role as genetic risk factors 
for development of autoimmune disease.  
MHC  class  II  genes  are  expressed  as  cell  surface  attached  alpha/beta 
heterodimers on specialized leukocytes (professional antigen presenting cells 
such as dendritic cells, macrophages and B-cells) and act mainly as cell surface 
receptors for processed antigens of extracellular origin. These peptide antigens 
are bound to the polymorphic antigen-presenting cleft of the class II molecule 
(Bjorkman et al., 1987). The size of peptides bound by class II molecules are 
usually  between  13-25  amino  acids  and  are  presented  by  MHC  class  II 
molecules to T-cell receptors on CD4
+ T helper cells. In the event of activation, 
helper T-cells will release cytokines and interleukins, which can alter various 
types of immune reactions, such as the regulation of antibody production. This 
process  is  important  for  initiating  the  immune  responses  against  infectious 
organisms but is also likely to be involved in immune-mediated or autoimmune 
diseases.  
A wide diversity and polymorphism exist within the MHC to ensure that 
individuals can respond to a large variety of antigens. The MHC class II genes 
encode extremely polymorphic class II antigens (Bontrop et al., 1999; Bach, 
1985). In humans there are > 1,800 different alleles identified at the HLA class 
II complex and the DRB1 locus is the most polymorphic (Robinson et al., 
2013). There are several systemic rheumatic diseases in both dogs and humans 
associated  with  the  MHC,  including  SLE  (Fernando  et  al.,  2008;  Smerdel-
Ramoya et al., 2005; Teichner et al., 1990).  
The classical MHC class II region in humans is called the HLA region and 
consists of DP, DQ and DR genes. The genes produce two glycoprotein chains, 
an  α-chain  and  a  β-chain  that  together  form  a  heterodimeric  structure  with 
extracellular domains (α1+α2 and β1+β2), where α1 and β1 forms the peptide 
binding cleft. DRβ forms heterodimers with DRα and DQα with DQβ. At least 
one  class  II  molecule  from  each  class  II  sub  region  (DR  and  DQ  in  dog) 
composed  of  an  alpha-beta  heterodimer  is  expressed  on  the  cell  surface  of 
antigen  presenting  cells  (Albert  et  al.,  1985).  The  highest  polymorphism 
(except DRα) is found in exon 2 of the α- and β-chains, which are involved in 
peptide binding (Little & Parham, 1999).  
The HLA complex is located on human chromosome 6p21.31 and extend 
approximately 4 Mb  (Complete sequence and gene map of a human major 
histocompatibility complex. The MHC sequencing consortium, 1999). Almost   26 
half  of  the  expressed  genes  within  this  region  (>120)  are  involved  in  the 
immune defense (Stewart et al., 2004).  
The MHC class II region differs markedly between species. Humans have 
one monomorphic HLA-DRA gene, four expressed HLA-DRB genes (DRB1, 
DRB3,  DRB4  and  DRB5)  (Andersson  et  al.,  1998)  (and  five  DRB 
pseudogenes),  one  expressed  HLA-DQA1  and  DQA2  gene  and  finally  one 
expressed  HLA-DQB1  and  DQB2  gene  (Robinson  et  al.,  2013).  In 
comparison,  the  feline  MHC  class  II  only  consists  of  44  genes,  with  an 
expansion of three DRA genes, seven different DRB genes and a lack of the 
entire DQ region (Yuhki et al., 2003).  
The dog MHC is called the dog leukocyte antigen (DLA) and consists of 
three classes. The DLA region is located on canine chromosome (CFA) 12, and 
the class II region is around 711 Kb in length. There are 45 loci of which 29 
are complete functional genes (five are unprocessed pseudogenes and 10 are 
processed  pseudogenes)  (Debenham  et  al.,  2005).  The  dog  has  one  DLA-
DRA1,  DLA-DRB1,  DLA-DQA1,  DLA-DQB1  gene,  respectively  and  one 
DLA-DQB2 pseudogene. DLA-DQB2 gene shares 98% identity with DLA-
DQB1 over 2562 bp (intron 2 to the end of exon 6) (Debenham et al., 2005; 
Wagner et al., 1999).  
In 2008, 67 DLA-DRB1 alleles, 21 DLA-DQA1 alleles and 54 DLA-DQB1 
alleles had been identified in the dog (Kennedy, 2013; Kennedy et al., 2001; 
Kennedy et al., 2000). Currently there are 300 DLA-DRB1, 51 DLA-DQA1 
and 150 DLA-DQB1 alleles identified, but all are not yet confirmed. 206 DLA-
DRB1, 37 DLA-DQA1 and 100 DLA-DQB1 alleles have been confirmed (L.J 
Kennedy,  personal  communication).  The  DLA-DRA1  locus  appears  to  be 
monomorphic. There is a large distribution of polymorphism between the class 
II loci. DRB is most polymorphic followed by DQB and DQA whereas DRA is 
largely monomorphic in all mammals studied. The functional reason for why 
DR  is  more  polymorphic  than  DQ  is  not  known  but  could  be  related  to 
requirement for different antigen presentation. 
There  is  a  large  inter-breed  variety  in  DLA  class  II  both  regarding  the 
observed allele frequencies and the number of identified alleles in each breed. 
A general frequency of approximately 30% homozygotes has been observed at 
all three loci. Number of alleles within a dog breed varies from 2 – 22 and 
often there are certain specific alleles that dominate in frequency in a breed 
(Kennedy et al., 2002). This interbreed variation could partly explain the fact 
that some breeds are susceptible to certain autoimmune or immune-mediated 
diseases.    27 
1.3.1  MHC is involved in several canine immune-mediated diseases 
The association between HLA and autoimmune disease in humans has been 
extensively reviewed during the past decades  and several associations have 
been identified (Fernando et al., 2008). Below follows a brief description of 
what is currently known within the field of canine autoimmune or immune-
mediated diseases and its association to MHC class II (summarized in Table 4).  
Canine diabetes mellitus occurs spontaneously in various breeds (Catchpole 
et al., 2005). Association between diabetes mellitus and DLA class II has been 
reported by Kennedy et al. who studied the disease in various breeds and found 
three  haplotypes  associated  with  the  disease  (DRB1*009/DQA1*001/ 
DQB1*008, DRB1*015/DQA1*0061/DQB1*023 and DRB1*002/DQA1*009/ 
DQB1*001) and one protective haplotype (DQA1*004/DQB1*013). A trend 
was observed between the breeds with DLA-DQA1*00101 as a shared risk 
factor between breeds (Kennedy et al., 2006b; Catchpole et al., 2005). 
Hypoadrenocorticism,  also  called  Addison's  disease,  is  a  deficiency  of 
corticosteroids and mineralocorticoids produced by the adrenal gland. A large 
number of breeds are predisposed to the disease. Several closely related alleles 
of the DLA-DRB1/DQA1/DQB1 in six different breeds show association to 
hypoadrenocorticism  (Springer  spaniel;  DRB1*01501/DQA1*00601/ 
DQB1*02301,  Labrador  retriever;  DLA-DRB1*00101/DQA1*00101/ 
DQB1*00201,  Bearded  collie;  DLA-DRB1*00901/DQA1*00101/DQB1* 
00802 and Cocker spaniel DLA-DRB1*00901/DQA1*00101/ DQB1*008011) 
(Massey et al., 2013a). Another study conducted in NSDTR found a haplotype 
related  to  the  previously  identified  as  the  risk  haplotype,  only  differing  at 
DLA-DRB1 (DLA-DRB1*01502/DQA*00601/ DQB1*02301) (Hughes et al., 
2010). Portuguese water dogs affected by hypoadrenocorticism are associated 
to a microsatellite marker located within the DLA region (Chase et al., 2006). 
Primary immune-mediated haemolytic anaemia is an autoimmune disease 
where  red  blood  cells  are  destroyed,  giving  rise  to  signs  of  anaemia.  Two 
haplotypes  (DRB1*01501/DQA1*00601/DQB1*00301  and  DLA-
DRB1*00601/DQA1*005011/DQB1*00701)  was  found  to  be  significantly 
associated with the disease in several breeds (Kennedy et al., 2006a).  
Chronic inflammatory Hepatitis in Dobermann is a chronic and progressive 
inflammatory liver disease with a suggested autoimmune etiology (Speeti et 
al., 2003; Meyer et al., 1980). Dobermanns homozygous for the risk haplotype 
DLA-DRB1*00601/DQA1*00401/DQB1*01303,  especially  with 
homozygosity for DLA-DRB1*00601 are susceptible to hepatitis. A protective 
effect  was  also  identified  (DLA-DQA1*00901/DQB1*00101  and  DLA-
DRB1*01501) (Dyggve et al., 2011). Another study including English springer   28 
spaniel identified two risk alleles (DRB1*00601 and DQB1*00701) and two 
protective alleles (DRB1*00501 and DQB1*00501) (Bexfield et al., 2012). 
Canine rheumatoid arthritis (CRA) or canine polyarthritis is described as 
symmetrical spontaneously occurring inflammatory polyarthritis (Bari et al., 
1989).  The  DLA-DRB1*002  allele  was  found  associated  in  several  breeds 
(Ollier et al., 2001). This allele contains the shared five amino acid epitope 
RARAA at amino acid positions 70–74. This is known as the shared epitope 
for rheumatoid arthritis in human (Gregersen et al., 1987). 
Symmetrical Lupoid Onychodystrophy is an immune-mediated disease in 
dogs and is described as separation and sloughing of several claws from claw 
beds and ultimately affecting all claws. The disease occurs in many breeds but 
Gordon setter has been reported to have a particularly high prevalence (Ovrebo 
Bohnhorst  et  al.,  2001).  We  have  reported  that  dogs  carrying  haplotype 
DRB1*01801/DQA1*00101/DQB1*00802  were  at  increased  risk  for 
developing  the  disease  and  that  the  risk  factor  was  even  stronger  in 
homozygous  form.  A  protective  haplotype  (DRB1*02001/DQA1*00401/ 
DQB1*01303) was also identified and the effect of the protective haplotype 
was clearly stronger than the risk haplotype (Wilbe et al., 2010b). 
Canine  Lymphocytic  Thyroiditis  (CLT)  is  characterized  by  autoimmune 
destruction of the thyroid gland with increased levels of thyroid-stimulating 
hormone (TSH) and sometimes presence of circulating autoantibodies against 
thyroglobulin (TgAA) (Dixon & Mooney, 1999; Nachreiner et al., 1998). A 
risk  haplotype  (DLA-DRB1*01201/DQA1*00101/DQB1*00201)  have  been 
identified in giant schnauzers for developing CLT and the same DQA1 risk 
allele has been observed in Dobermanns and in a variety of additional breeds 
(Wilbe et al., 2010a; Kennedy et al., 2006c; Kennedy et al., 2006d). In our 
study, protection for the disease was also identified in dogs carrying another 
haplotype (DRB1*01301/DQA1*00301/DQB1*00501) (Wilbe et al., 2010a). 
Canine  anal  furunculosis  affects  German  shepherd  dogs.  This  is  an 
inflammatory  disease  of  the  perianal  tissues.  The  disease  is  believed  to  be 
immune-mediated  with  evidence  of  response  to  immunosuppressive  drugs 
(Hardie et al., 2005). Kennedy et al. found strong genetic association to the 
DLA-DRB1*00101  allele  and  that  homozygosity  for  DRB1*00101  had  an 
earlier onset of anal furunculosis (Barnes et al., 2009; Kennedy et al., 2008). 
Necrotizing  meningoencephalitis  in  dogs  is  an  autoimmune  disease.  It 
occurs in many different breeds but the Pug dogs share clinical similarities 
with several acute forms of multiple sclerosis in humans. MHC class II was 
shown  to  be  a  genetic  risk  factor  where  the  haplotype 
(DRB1*0100110/DQA1*00201/DQB1*01501)  was  found  to  be  associated 
with increased risk. Homozygosity gave an even higher risk for disease and a   29 
protective  effect  was  observed  (DRB1*01502/DQA1*00601/DQB1*02301) 
(Greer et al., 2010).  
Uveodermatologic syndrome is an immune-mediated disease characterized 
by inflammatory infiltrates and loss of melanocytes in affected tissues (eye and 
skin) that ultimately causes blindness. The disease is highly predisposed in the 
American  Akita  breed.  Angles  et  al  found  that  DLA-DQA1*00201  was 
significantly associated with the syndrome (Angles et al., 2005). 
Canine chronic superficial keratitis is an inflammatory ocular disease of 
autoimmune nature. A risk haplotype (DLA-DRB1*01501/DQA1*00601/ 
DQB1*00301)  was  associated  with  disease  in  German  shepherd  dogs. 
There was also an increased risk for dogs homozygous for the risk haplotype 
and an increased risk associated with general homozygosity of the MHC class 
II (Jokinen et al., 2011). 
Polymyositis is frequently observed in the Hungarian Vizsla. An immune-
mediated  etiology  has  been  suggested.  A  risk  haplotype  (DLA-
DRB1*02001/DQA1*00401/DQB1*01303)  was  identified  and  the  risk 
increased for homozygotes (Massey et al., 2013b). 
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Table 4. Identified DLA associations with canine autoimmune or immune-mediated diseases. 
Condition  Comment  Breeds  References 
Canine diabetes mellitus  Suggested immune-
mediated disease 
Range of breeds; 
Samoyed, Cairn 
and Tibetan terrier 
(Kennedy et al., 
2007; Kennedy et al., 
2006b; Catchpole et 
al., 2005) 
Hypoadrenocorticism  Suggested 
autoimmune disease 
Nova Scotia duck 
tolling retriever 
(Massey et al., 
2013a; Hughes et al., 
2010; Chase et al., 
2006) 
Primary immune-mediated 
haemolytic anaemia 
Suggested 
autoimmune disease 
Range of breeds  (Kennedy et al., 
2006a) 
SLE related immune-
mediated rheumatic disease  
Suggested 
autoimmune disease 
Nova Scotia duck 
tolling retriever 
Paper I and III 
Chronic inflammatory 
hepatitis 
Suggested 
autoimmune disease 
Dobermann  (Bexfield et al., 
2012; Dyggve et al., 
2011) 
Canine rheumatoid arthritis  Autoimmune disease. 
RA shared epitope 
Range of breeds  (Ollier et al., 2001) 
Symmetrical lupoid 
onychodystrophy 
Immune-mediated 
disease 
Gordon setter  (Wilbe et al., 2010b) 
Bearded collie 
Giant schnauzer 
Canine Lymphocytic 
thyroiditis 
Autoimmune disease  Range of breeds;  (Wilbe et al., 2010a; 
Kennedy et al., 
2006c; Kennedy et 
al., 2006d) 
Dobermann 
Giant schnauzer 
Canine anal furunculosis  Immune-mediated 
disease 
German shepherd  (Barnes et al., 2009; 
Kennedy et al., 2008) 
Necrotizing 
meningoencephalitis 
Suggested 
autoimmune disease 
Pug   (Greer et al., 2010) 
Uveodermatologic (VKH-
like) syndrome 
Immune-mediated 
disease 
Akita  (Angles et al., 2005) 
Canine chronic superficial 
keratitis 
Suggested 
autoimmune disease 
German shepherd  (Jokinen et al., 2011) 
Polymyositis	
 ﾠ Suggested immune-
mediated disease 
Hungarian Vizsla  (Massey et al., 
2013b) 
 
Thus,  many  canine  autoimmune  or  immune-mediated  diseases  have  shown 
DLA  class  II  association.  It  is  important  to  remark  that  although  DLA-
DRB1/DQA1/DQB1  genes  are  encoding  proteins  that  are  functionally 
confirmed to control immune responses, they are only markers for the disease 
risk until functional experiments have been performed to confirm the risk. This 
is due to the high LD within MHC in all species and in particular in dogs 
where the extensive inbreeding further increases LD that occurs within a dog   31 
breed. Many other genes important for immune function is located within the 
DLA region and can carry the functional mutation/s.  
However, functional studies using transgenic mice have shown that MHC 
class II is sufficient for inducing autoimmune diseases. E.g. transgenic mice 
expressing  HLA-DQ8,  a  gene  in  linkage  with  DR4  associated  with 
susceptibility with rheumatoid arthritis, were produced. The mice showed a 
collagen-induced  arthritis  and  became  an  important  animal  model  to  study 
human  autoimmune  arthritis  and  suggesting  that  HLA-DQ  molecule  might 
have  an  important  role  in  determining  susceptibility  to  rheumatoid  arthritis 
(Nabozny et al., 1996). 
In this thesis we have added one more breed to the studies of autoimmune 
or immune-mediated diseases and its association to MHC class II, the SLE-
related disease complex in NSDTR.  
1.3.2  General risk in homozygosity  
The selective breeding practice has caused a reduced genetic variation and an 
increase  in  homozygosity  (Lindblad-Toh  et  al.,  2005).  This  can  also  be 
observed  in  the  MHC  class  II  of  the  dog,  where  several  autoimmune  or 
immune-mediated diseases show an increased risk if the associated haplotype 
occurs  in  homozygous  form.  A  homozygous  risk  haplotype  have  been 
identified in dogs affected by symmetrical lupoid onychodystrophy (Wilbe et 
al., 2010b), canine chronic superficial keratitis (Jokinen et al., 2011), chronic 
inflammatory  hepatitis  in  Dobermann  (Dyggve  et  al.,  2011),  necrotizing 
meningoencephalitis (Greer et al., 2010), polymyositis (Massey et al., 2013b), 
earlier onset of canine anal furunculosis (Kennedy et al., 2008) and the SLE-
related disease in NSDTRs, presented in this thesis (Paper I and III).  
A  general  risk  in  homozygosity  at  DLA  class  II  have  been  observed, 
independent of haplotype, in canine chronic superficial keratitis (Jokinen et al., 
2011) and hypoadrenocorticism (Massey et al., 2013a) and in ANA
H dogs with 
the  SLE-related  disease  presented  in  this  thesis  (Paper  III).  Dogs  with 
hypoadrenocorticism tend to have an earlier onset of disease if homozygous 
(Hughes  et  al.,  2010).  No  protective  homozygous  haplotype  have  been 
observed. The fact that homozygosity at DLA class II leads to differential risk 
for  developing  immune-mediated  disease  is  expected  to  be  caused  by  the 
ability  of  presentation  of  autoantigens  by  the  risk  DLA  but  not  by  the 
protective DLA class II molecules. MHC class II heterozygotes can express a 
wider variety of class II molecules than homozygotes, thereby being able to 
respond  to  larger  diversity  of  pathogens.  The  finding  is  in  agreement  with 
rodent  models  for  experimentally  induced  autoimmune  disease  where  high-   32 
and low responder strains (differing only at MHC) develop disease at different 
levels upon challenge with the inducing antigens (Holmdahl, 2003). 
Heterozygosity at MHC appears advantageous in most natural populations. 
The prevailing hypothesis is that the selection for high degree of MHC class II 
polymorphism is pathogen-driven (Borghans et al., 2004). Polymorphism is 
maintained because of heterozygote advantage in the individual of being able 
to present a larger repertoire of peptide antigens and thus increase the chance 
of mounting an immune response towards pathogenic microorganisms. Thus, 
MHC polymorphism is maintained because of selective pressure imposed by 
different  pathogens  occurring  in  a  population’s  environment  (Havlicek  & 
Roberts,  2009).  There  are  two  classical  examples  for  this.  The  first  was 
described  in  chicken  where  Marek’s  disease  was  shown  to  be  caused  by  a 
particular herpes-like virus and that the chicken with certain MHC types were 
susceptible  and  chickens  with  other  MHC  types  were  resistant  leading  to 
frequency-dependent  selection  for  the  chickens  with  resistant  MHC  types 
(Longenecker et al., 1977). The other example is malaria in humans, where 
humans  with  HLA  class  II  haplotype  DRB1*1302/DQB1*0501  are  able  to 
defend  the  malaria-inducing  trypanosomal  parasite  leading  to  increased 
frequency  of  the  protective  MHC  type  in  West  Africa  where  malaria  is 
common (Hill et al., 1991). It has also been shown that certain HLA class I 
alleles influence HIV progression (Carrington & O'Brien, 2003). 
The exceptions to the general observation of high MHC polymorphism in 
natural mammalian populations are found either among solitary species or in 
populations that have experienced bottle-necks due to high hunting pressure or 
to other environmental factors (O'Brien & Yuhki, 1999; Mikko & Andersson, 
1995; Ellegren et al., 1993) Last, MHC variation has shown to be preserved 
because of sexual selection, where individuals prefer to mate with a partner 
with dissimilar MHC genotype to their own (Wedekind & Furi, 1997; Potts et 
al., 1991).      33 
2  Aims of this Thesis 
The overall aim of this research project was to identify genetic risk factors for 
the  immune-mediated  diseases  IMRD,  which  is  an  SLE-related  disease 
complex,  and  SRMA,  aseptic  meningitis,  in  the  canine  breed  NSDTR.  In 
particular, the IMRD disease type characterized by a positive ANA phenotype 
was  studied.  Identification  of  novel  genes  important  for  this  SLE-related 
disease may have major importance for both dog and human health. 
 
The specific aims were to: 
 
￘  Perform a candidate gene study to investigate if DLA class II is associated 
with the canine SLE-related disease and SRMA. 
 
￘  Investigate  if  genome-wide  association  mapping  identifies  additional 
susceptibility loci for the SLE-related disease and SRMA. 
 
￘  Perform regional re-sequencing of associated regions to identify specific 
genes and genetic variants involved in the disease and perform expression 
studies of positional candidate genes. 
 
￘  Evaluate whether differential gene expression of the gene variants carried 
on  risk  versus  control  haplotypes  is  associated  with  IMRD  with  the 
speckled ANA phenotype. 
 
￘  Characterize  the  relationship  between  ANA  type  (speckled  and 
homogenous)  and  the  genetic  constitution  at  DLA  class  II  and  other 
identified risk loci for IMRD.  
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￘  Identify novel genes and pathways associated with the canine SLE-related 
disease complex. 
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3  Present Studies 
3.1  Introduction 
The studies (Paper I-III) presented in this thesis aims to identify genetic risk 
factors for an SLE-related disease complex in the dog NSDTR. The IMRD 
complex has previously been described (Hansson-Hamlin & Lilliehook, 2009) 
and  since  the  NSDTR  breed  is  overrepresented  for  the  disease,  genetic 
components  are  suggested  to  be  involved  in  development  of  this  disease 
complex. No specific mode of inheritance has been reported, but it appears to 
be a multifactorial disease. DLA class II has previously been reported to be 
involved  in  several  autoimmune  and  immune-mediated disease in dogs and 
humans (Bexfield et al., 2012; Dyggve et al., 2011; Jokinen et al., 2011; Greer 
et al., 2010; Hughes et al., 2010; Wilbe et al., 2010a; Wilbe et al., 2010b; 
Barnes et al., 2009; Kennedy et al., 2008; Kennedy et al., 2006b; Kennedy et 
al., 2006d; Smerdel-Ramoya et al., 2005; Graham et al., 2002; Ollier et al., 
2001),  Therefore,  a  candidate  gene  approach  was  performed  to  investigate 
whether the DLA class II is a genetic risk factor for this SLE-related disease 
complex.  
We also performed an unbiased search of the entire genome in an effort to 
identify additional genetic risk factors by using a GWAS. The DLA class II 
region  contains  several  highly  polymorphic  genes  and  all  alleles  were  not 
covered in the canine 22K SNP chip array used in these studies. Therefore, the 
optimal way to explore whether DLA class II is a genetic risk factor for the 
disease complex was by performing a separate sequence-based candidate gene 
study.   36 
3.2  Methods and results 
3.2.1  Dog samples  
All dogs included in the studies described in Paper I-III were purebred and 
privately owned. All owners approved their dogs to participate in the study by 
filling out an owner’s consent form. Ethical permission was granted by the 
Ethical  board  for  experimental  animals  in  Uppsala,  Sweden  (Dnr  C138/6). 
Samples  were  obtained  by  a  close  contact  with  different  veterinary  clinics 
throughout  Sweden,  by  visiting  NSDTR  competitions  and  shows,  attending 
breed club meetings and by direct contact with dog owners with interest to 
participate in the study. Samples were collected during 2002-2013. 
Veterinarians selected dogs to be included in the studies based on strict 
inclusion  and  exclusion  criteria  following  examination.  To  be  classified  as 
affected by IMRD the dogs had to display musculoskeletal signs consistent 
with symmetrical polyarthritis and suffer from pain affecting several joints of 
extremities and display stiffness, mainly after rest. Signs needed to be apparent 
for at least 14 days. A positive IIF-ANA titre further strongly supported the 
diagnosis and classified the dogs as ANA-positive IMRD. Dogs classified as 
SRMA-affected display high fever and strong pain mainly from the neck and 
respond  to  corticosteroid  treatment. The  diagnosis  is  supported  by 
cerebrospinal fluid showing a significant neutrophilic pleocytosis. These dogs 
have a negative ANA-test. Dogs fulfilling the exclusion criteria were the dogs 
with no clinical signs of any autoimmune disease and >7 years of age.  
EDTA blood and serum samples were collected for all dogs included in the 
study population (Paper I-III).  Genomic  DNA  was  purified  from  200  µl  of 
blood using a commercially available kit, Qiagen QIAamp DNA Blood Mini 
Kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. For 
Paper III, we also collected peripheral blood from 165 healthy NSDTR dogs in 
Tempus Blood RNA tubes (Applied Biosystems, Foster City, CA). Samples 
were kept on ice during transportation and RNA was purified from total blood 
using  the  Tempus  Spin  RNA  Isolation  Reagent  kit  (Applied  Biosystems) 
according to the manufacturer’s instructions. 
3.2.2  IIF ANA procedure 
Serum samples were used for Indirect Immunofluorescence (IIF)-ANA tests. 
The diagnostic procedures were performed at the University Animal Hospital, 
SLU, Uppsala, Sweden using monolayers of HEp-2 cells fixed on glass slides 
(Immuno Concepts, Sacramento, CA). Slides were examined by fluorescence 
microscopy  and  the  nuclear  fluorescence  pattern  was  used  to  subdivide  a 
positive ANA result into either a homogenous or a speckled pattern (Hansson-  37 
Hamlin et al., 2006). The test was considered positive at a titre of ≥1:100. 
Positive ANA tests were divided into either a speckled (ANA
S) or homogenous 
(ANA
H) staining pattern and tests were repeated after two-three months. The 
ANA phenotype was assigned to a dog if two subsequent tests performed on 
samples  taken  from  the  same  dog  were  consistent.  Sera  from  all  healthy 
controls  were  negative  on  the  IIF-ANA  test.  Only  one  IIF-ANA  test  was 
performed on healthy dogs, because no dogs without clinical signs have ever 
showed a positive test.  
3.2.3  DLA class II in ANA-positive dogs  
In Paper I, we investigated the possible role of MHC class II as a genetic risk 
factor in IMRD and SRMA by sequence-based typing of the polymorphic exon 
2 of the DLA-DRB1, -DQA1 and -DQB1 loci in the DLA class II region. In 
paper III we further correlated MHC class II genotype with the ANA-staining 
pattern in IMRD dogs. PCR (polymerase chain reaction) fragments containing 
DLA-DRB1, -DQA1 and -DQB1 exon 2 sequences were amplified, purified 
and  sequenced  using  capillary-electrophoresis.  Data  analysis  of  the  exon  2 
nucleotide  sequences  for  DLA-DRB1,  -DQA1  and  -DQB1  were  performed 
with  MatchTools  and  MatchToolsNavigator  (Applied  Biosystems).  2x2 
Contingency Tables were used to calculate OR, 99% Confidence Interval and 
p-values. Cases and controls were divided into presence or absence of each 
allele, haplotype or genotype and the total number of individuals in each group 
was  calculated.  A  comparison  was  made  between  the  cases  and  controls 
between total number of alleles, haplotypes and genotypes in each group.  
In Paper I, a total of 176 dogs including 51 IMRD (33 ANA-positive), 49 
SRMA cases and 78 healthy controls (two dogs were affected by both IMRD 
and SRMA) were included in the analysis.  
A total of five DLA-DRB1, four DLA-DQA1 and four DLA-DQB1 alleles 
were identified forming five different haplotypes and 13 genotypes. Haplotype 
2  (DLA-DRB1*00601/DQA1*005011/DQB1*02001)  occurred  in  increased 
frequency  in  all  IMRD  ANA-positive  cases  together  compared  to  controls 
(54.5% vs. 34.6%, OR= 2.3). An even stronger association was found in all 
ANA-positive  dogs  homozygous  for  haplotype  2  (genotype  2)  (48.5%  vs. 
11.5%, OR= 7.2). No association to DLA class II was observed for SRMA-
affected dogs. 
In the subsequent study (Paper III), we increased the number of NSDTR 
with IMRD and a positive ANA test. A total of 64 cases were ANA-positive 
(26  cases  were  classified  as  ANA
H  and  32  cases  as  ANA
S).  Six  of  the  64 
clinical cases were not analyzed for ANA subgroup due to lack of more serum. 
All 78 healthy control sera were negative for IIF ANA.   38 
We  investigated  for  DLA  class  II  association  and  further  dissected  the 
phenotype  by  dividing  the  ANA-positive  cases  into  ANA
H  and  ANA
S  to 
determine whether dogs with different types of ANA pattern has differential 
genetic  association  to  DLA.  The  same  number  of  alleles,  haplotypes  and 
genotypes  were  observed  as  in  our  previous  study  (Paper  I).  A  similar 
association in this larger sample set was observed for all ANA-positive dogs 
jointly for haplotype 2 (50.8% vs. 34.6%, OR= 2.0) and genotype 2 (45.3% vs. 
11.5%, OR= 6.4). Among the ANA
S dogs, 30 of 32 were either heterozygous 
or  homozygous  for  haplotype  2  and  26  of  those  were  homozygous  for 
haplotype  2  (81.3%,  OR=  33.2)  implicating  that  homozygosity  for  the  risk 
DLA class II haplotype results in increased risk of developing IMRD with the 
ANA
S  phenotype.  No  significant  association  was  observed  between  the 
different haplotypes or genotypes of MHC class II and the cases with ANA
H 
pattern.  
We next removed the ANA
S risk genotype and analyzed that data based on 
homozygosity.  An  increase  in  homozygosity  was  seen  in  ANA
H  cases 
compared  to  controls  (62.5%  vs.  13.0%  OR=  11.1),  implicating  a  general 
disadvantage due to homozygosity at DLA class II for ANA
H dogs (Table 5). 
Table 5. Homozygous frequencies show an association to both ANA
S and ANA
H dogs. Genotype 
2 frequencies show an increased risk in ANA
S dogs. By removing the risk genotype, a significant 
association is identified for ANA
H dogs in general homozygosity at DLA. Significant associations 
are indicated in bold. 
  Tot pop % 
n=142 
Controls % 
n=78 
All cases
 % 
n=64 
ANA
S % 
n=32 
ANA
H % 
n=26  
Homozygous  45.8 (65)  23.1 (18)  73.4 (47)  84.4 (27)  65.4 (17) 
Genotype 2  26.8 (38)  11.5 (9)  45.3 (29)  81.3 (26)  7.7 (2) 
  Tot pop % 
n=104 
Controls % 
n=69 
All cases
 % 
n=35 
ANA
S % 
n=6 
ANA
H % 
n=24  
Homozygous no risk   26.0 (27)  13.0 (9)  51.4 (18)  16.7 (1)  62.5 (15) 
S= Speckled 
H= Homogenous 
 
3.2.4  GWAS identifies five additional loci 
To perform a systematic and unbiased search of the entire dog genome for 
additional  genetic  risk  factors  a  GWAS  was  conducted  (Paper  II).  A  case-
control  association  analysis  of  138  NSDTR  from  the  Swedish  and  Finnish 
populations (44 SRMA dogs, 37 IMRD (where 22 were ANA-positive) and 57 
healthy controls) was performed. All dogs used for the GWAS were unrelated   39 
at the grandparental level. Genotyping was performed with the CanineSNP20 
BeadChip panel that contains 22,000 validated SNPs.  
We hypothesized  that  IMRD  and  SRMA  might  have  both  common  and 
unique genetic risk factors and therefore examined the diseased dogs both as 
one  group  and  for  the  classified  sub-phenotypes,  ANA-positive  IMRD  and 
SRMA  separately.  To  test  for  the  presence  of  stratification  in  our  sample 
population we used PLINK (Purcell et al., 2007) to make multidimensional 
scaling plots. We then produced scatter plots for two dimensions in which each 
spot  corresponds  to  a  specific  individual.  Some  stratification  was  observed 
when all diseased dogs were analyzed together and for the SRMA-affected 
dogs alone. We therefore used PLINK to correct for population stratification 
based  on  clustering  by  identity-by-state,  thereby  accounting  for  population 
substructure to lower false positive rates and increase power.  
Analysis of all cases (IMRD and SRMA) as one group identified a large 
region containing multiple associated SNPs on CFA 32 (praw= 1.5 x 10
-5 and 
pgenome=  0.12).  After  correction  for  stratification,  the  region  showed  even 
stronger association (praw= 7.9 x 10
-6 and pgenome= 0.06) (Figure 3). 
Four  highly  associated  regions  were  identified  when  analyzing  ANA-
positive IMRD dogs separately. The strongest association was found for one 
SNP on CFA 8 (praw= 1.5 x 10
-6 and pgenome= 0.02) and a region containing 
multiple SNPs on CFA 24 (praw= 3.2 x 10
-6 and pgenome= 0.04), both reaching 
genome-wide significance. We also found multiple associated SNPs on CFA 
11 (praw= 7.4 x 10
-6 and pgenome= 0.08) and on CFA 3 (praw= 2.2 x10
-5 pgenome= 
0.18) (Figure 3). The associated peaks were the same when all IMRD-affected 
dogs  were  included  (data  not  shown)  as  when  only  ANA-positive  IMRD-
affected dogs were used, but with a weaker degree of association.  
When  analyzing  all  SRMA-affected  dogs  separately,  one  region  with 
multiple associated SNPs was identified on CFA 32 (praw= 7.10 x 10
-6 and 
pgenome= 0.04) reaching genome-wide significance (Figure 3).    40 
 
Figure 3. Five strongly associated regions were detected in the study population. One locus on 
CFA  32 was identified in all diseased dogs (black). Four loci on CFA  3, 8, 11 and 24 was 
associated with ANA-positive dogs (blue) and one loci (CFA 32) was identified in SRMA dogs 
(red).  
The associated regions had large haplotype sizes (mostly ≈1 Mb in size), as 
expected within a canine breed (Lindblad-Toh et al., 2005). However, a couple 
of regions were larger suggesting the possibility that genetic risk is caused by 
multiple nearby loci or extended LD within this region.  
3.2.5  Fine-mapping verifies the loci 
To  validate  associated  loci  from  the  GWAS,  we  performed  fine-mapping 
(Paper II). Additional NSDTR and dogs from other breeds were included to 
reach a total number of 405 dogs. The sample consisted of 82 IMRD cases (32 
ANA-positive, not divided into speckled and homogenous staining), 78 SRMA 
cases  and  176  controls.  Additional  breeds,  with  individuals  affected  by 
corresponding diseases and control dogs, were included to allow identification 
of shared haplotypes across breeds. ANA-positive dogs were represented by 19 
German shepherds (five cases and 14 controls) and 10 cocker spaniels (six 
cases and four controls), while for SRMA-affected dogs we used 30 boxers (10 
cases and 20 controls) and 10 petite basset griffon Vendeen (four cases and six 
controls).    41 
822 SNPs at ≈1 SNP/10 Kb density were genotyped. SNPs were analyzed 
with PLINK with MAF > 0.1 and call rate > 80%. The same settings were used 
to analyze haplotypes generated with a sliding window approach provided by 
PLINK. 
Due to the low number of samples, examination for shared haplotypes was 
performed without prior association in the other breeds. However, they could 
be used for haplotype sharing across breeds. 
For ANA-positive dogs, three of the four peaks showing association in the 
GWA analysis also showed increased p-values for association with the disease 
at the fine-mapping level, whereas one locus showed weaker association (CFA 
8)  in  the  fine-mapping  analysis.  The  SNP  showing  the  strongest  genetic 
association was found on CFA 11 (praw= 8.7 x 10
-13, OR= 7.9) and resides 
within a highly associated haplotype (praw= 1.3 x 10
-12). The candidate region 
contains  the  EPB41L4B,  C9orf4  and  PTPN3  genes.  The  second  best 
association results was a haplotype on CFA 24 (praw= 1.6x10
-12, OR= 5.0), 
including  six  genes,  AK128395,  WFDC10B,  WFDC13,  AY372174,  WFDC1 
and DNTTIP1. The association on CFA 3 includes a haplotype (praw= 2.2 x   
10
-11 and OR= 4.5) containing seven genes, AK126887, AP3B2, SCARNA15, 
FSD2, RPL23A, WHDC1L1 and HOMER2. The GWA hit on CFA 8 became 
lower  after  fine-mapping  for  ANA-positive  dogs  and  was  therefore  not 
considered validated for ANA-positivity alone.  
The region on CFA 32 also showed association to ANA-positive dogs alone 
(praw= 3.5 x 10
-7,
 OR= 3.3). This is a large region (1.6 Mb) that includes several 
genes,  DAPP1,  MAP2K1IP1,  DNAJB14,  DDIT4L,  EMCN,  PPP3CA  and 
BANK1.  
For SRMA, the region on CFA 32 was validated (praw= 2.4 x 10
-7, OR= 0.3) 
and contains the genes DAPP1, MAP2K1IP1, DNAJB14 and H2AFZ. A novel 
association for SRMA dogs alone was identified on CFA 8 (praw= 3.2 x 10
-7,
 
OR= 2.6). The peak resides in a gene desert between the SNRPE and VRK1 
genes.  
When all cases were analyzed together, the main peak of association on 
CFA 32 remained at approximately the same strength (praw=4.4 x 10
-6, OR= 
3.0). The region remains large and appears to comprise three peaks, positioned 
at the genes DAPP1, PPP3CA and BANK1. Since the association is present in 
multiple phenotypes, it is possible that it contains one or more risk alleles.  
3.2.6  Targeted re-sequencing of candidate loci 
We next performed targeted re-sequencing of associated regions (Paper III). 
The five regions (CFA 3, 8, 11, 24 and 32), spanning approximately 5Mb, were 
re-sequenced in seven individuals (four ANA-positive
 cases and three healthy   42 
controls),  using  hybrid  capture  and  400-600  X  coverage,  with  Illumina 
sequencing, in order to identify candidate mutations. The sequencing data were 
aligned  with  Burrows-Wheeler  Aligner  (BWA)  (Li  &  Durbin,  2010). 
SAMtools (Li et al., 2009) was used for SNP and InDel calling, BEDTools 
(Quinlan  &  Hall,  2010)  for  calculations  of  coverage  statistics  and  finally 
SEQscoring (Truve et al., 2011) to visualize the data and discover differences 
in the genomic sequence, such as SNPs, InDels and CNVs, between ANA-
positive IMRD and healthy control dogs.  
A total of 13,084 potential SNPs were detected and of these, 426 SNPs 
were located within or close (±5 bp) to a conserved element (Lindblad-Toh et 
al., 2011; Garber et al., 2009). 2780 possible InDels were detected, among 
those, 88 occurred within or close to a conserved element (±5 bp). To identify 
structural variations, such as larger insertions, CNV or deletions SEQscoring 
(Truve et al., 2011) was used to calculate coverage differences between cases 
and controls. We did not identify any structural variants that differed between 
cases and controls. 
3.2.7  ANA
S association to DLA class II, CFA 11 and 32 
We next combined the results from DLA class II association study with the 
additional identified risk loci (Paper III). Twenty-five of the ANA
S-positive 
NSDTRs with MHC class II genotype 2 were included for additional analysis 
as well as 145 healthy controls and a total of 63 ANA-positive dogs (regardless 
of ANA-staining pattern). 384 SNPs for the five identified loci (CFA 3, 8, 11, 
24 and 32) were chosen from the next generation sequencing data set. The 
SNPs were chosen based on the following criteria:  
 
￘  Difference in allele frequency in cases compared to controls 
￘  Positioned in either protein coding regions, 5’ UTR or 3’ UTR  
￘  Located within non-coding conserved elements 
 
Conserved  elements  were  identified  using  comparative  sequence  analysis 
based on the analysis of 29 mammals using SiPhy (Lindblad-Toh et al., 2011; 
Garber et al., 2009). We examined the GWA risk loci on CFA 3, 8, 11, 24 and 
32 for association to the speckled phenotype (ANA
S).  
Strong associations to CFA 11 and 32 were observed in DLA haplotype 2 
homozygous ANA
S dogs. None of the other chromosomal regions showed a 
significant  association.  The  region  on  CFA  11  covering  the  PTPN3  gene 
comprised a haplotype of 15 SNPs that was highly associated to ANA
S dogs 
(most associated SNP, p= 8.2 x 10
-07, OR= 5.7). The most associated region on 
CFA 32 (p= 1.5 x 10
-08-4.7 x 10
-05 and OR= 3.4-6.8) is 1.3 Mb in size and 23   43 
SNPs show significant p-values. The region contains several genes, including 
DAPP1,  MAP2K1IP1,  DNAJB14,  H2AFZ,  DDIT4L,  EMCN,  PPP3CA  and 
BANK1 and the most associated SNP (32:24556037) is located upstream of 
DAPP1. One highly associated haplotype comprising two SNPs in high LD 
was also identified (32:24556037 and 32:25485961). 
Similar levels of association were observed between the CFA 11 region and 
ANA
S dogs, implying that this region is more important for ANA
S dogs since 
fewer  dogs  were  used  to  achieve  the  same  statistical  significance  for  the 
association. The region on  CFA  32 shows more significant P-values in the 
ANA
S  group  compared  to  all  ANA,  suggesting  that  this  region  is  most 
important for IMRD ANA
S–positive dogs.  
3.2.8  Multi locus analysis 
A multi locus analysis was performed to analyze the combined contribution of 
other risk factors at MHC class II, CFA 11 and 32. In total we had 56 healthy 
controls and 26 IMRD dogs with ANA
S–positivity with genotype data on all 
three loci (MHC class II, CFA 11 and 32). Among the 56 healthy controls, nine 
dogs were homozygous for the MHC risk genotype 2 and the other had either 
one copy of it (23 dogs) or none (24 dogs). 44.4% lacked additional risk loci, 
33.3% had one extra risk locus, 22.2% had two extra risk loci and none had 
three additional risk loci. 
Among IMRD ANA
S-positive dogs,  23 out of 26 were homozygous for 
haplotype 2, one was heterozygous and the other two had no MHC class II risk. 
Among the dogs homozygous for haplotype 2, 39.1% had zero additional risk 
factors, 17.4% had one additional risk factor, 34.8% had two additional risk 
factors and 8.7% had three additional risk factors. 
The nine control dogs with MHC risk had a total of seven risk haplotypes 
for the additional loci, which gives an additional contribution of 19.4%. There 
were  26  additional  risk  haplotypes  out  of  the  23  ANA
S  homozygous  dogs 
which gives and additional contribution of 28.3%. 
3.2.9  Expression studies of candidate genes 
Peripheral blood mononuclear cells (PBMC) were collected from 165 healthy 
dogs to prepare RNA to be used to measure the mRNA expression levels for all 
candidate genes within associated regions on CFA 11 (PTPN3) and CFA 32 
(DAPP1,  MAP2K1IP1,  DNAJB14,  DDIT4L,  EMCN,  PPP3CA  and BANK1). 
These genes were selected because they are located at the highest associated 
SNP or within the most associated haplotype. The dogs were genotyped for 
risk  and  non-risk  SNPs/haplotypes  and  correlated  to  the  level  of  gene 
expression.    44 
Three  SNPs  (11:67,516,041,  11:67,538,032  and  11:67,538,806)  in  the 
highly associated 15 SNP haplotype on CFA 11, spanning the PTPN3 gene, 
were genotyped in the healthy dogs. No dogs homozygous for the whole risk 
haplotype on CFA 11 were present in the healthy group. Among the ANA
S 
patients in the genetic study, only four dogs were homozygous for the risk 
haplotype  on  CFA  11  and  all  of  them  showed  very  severe  IMRD  that 
eventually led to death. Therefore, a SNP in the close vicinity of the haplotype 
(also  associated  p=  7.5  x  10
-4)  where  all  three  genotypes  occur  (position 
11:67583604)  was  genotyped.  This  four  SNP  haplotype  was  used  for 
correlation with expression. An 8-fold downregulation of PTPN3 mRNA levels 
(p= 0.013) was identified in dogs carrying the risk haplotype. 
All  genes  on  the  large  region  (1.3  Mb)  on  chromosome  32  were  also 
analyzed for differential expression and correlated to genetic association. Two 
of them, DDIT4L (3-fold, p=0.0002) and BANK1 (1-fold, p=0.006), show an 
upregulation  of  mRNA  expression  related  to  the  two  SNP  haplotype 
(32:24556037  and  32:25485961).  A  modest  upregulation  of  DAPP1  and 
PPP3CA is correlated with the SNP (32:24890208), which is included in a risk 
haplotype but not associated alone. 
3.3  Discussion 
In Paper I we performed a case/control candidate gene approach by sequencing 
the polymorphic exon 2 of the DLA-DRB1, -DQB1 and –DQA1 class II genes. 
We also (Paper II) performed a GWAS followed by fine-mapping in an effort 
to identify additional genetic risk factors. MHC class II was identified as a risk 
factor for both ANA
S and ANA
H IMRD dogs but not for SRMA dogs. Four 
additional risk factors for the ANA-positive phenotype were identified by a 
GWAS (CFA 3, 11, 24 and 32), where CFA 11 and 32 were associated to the 
speckled  phenotype  (Paper  III).  Expression  studies  revealed  that  PTPN3, 
DDIT4L  and  BANK1  have  different  expression  according  to  risk/non  risk 
haplotype identified for ANA
S dogs (Paper III) and that several different cell 
types, such as T-cells, B-cells and possibly macrophages are involved. 
We demonstrated that the dog is an excellent model for studying complex 
genetic disease and that only few cases and controls are needed to identify 
genetic risk factors underlying a complex genetic disease.  
3.3.1  DLA class II is a genetic risk factor 
In Paper I and III, we identified MHC class II as an important genetic risk 
factor for ANA-positive IMRD dogs. A particular homozygous risk haplotype 
was  identified  in  ANA
S  dogs  and  a  general  homozygous  disadvantage  was   45 
found in ANA
H dogs. The observed association with an OR at 33 is one of the 
highest reported for an autoimmune disease and MHC class II, suggesting that 
MHC class II is probably of major importance for development of IMRD with 
the ANA
S phenotype in dogs.  
Only two ANA
S dogs lack haplotype 2 and both are slightly atypical IMRD 
cases. One of the cases showed clinical signs from multiple organ systems in a 
way not usually observed in NSDTRs diagnosed with IMRD. Clinical signs 
shown  by  this  dog  were  skin  necrosis  on  ear  flaps  and  around  the  mouth, 
weight loss and muscle atrophy of the head muscles, apart from the joint pain 
and stiffness indicating a rheumatic disease. Finally this patient was euthanized 
due to breathing problems. This dog had MHC class II genotype 6 and only the 
risk factor at chromosome 11. The other dog was diagnosed with SRMA at 10 
months  of  age  and  it  was  treated  with  corticosteroids  and  recovered 
completely. Later on, at two years of age, the dog was diagnosed with IMRD 
and had become ANA-positive. In this material, this is the only dog suffering 
from both SRMA and IMRD (data not shown). This dog was homozygous for 
MHC class II (genotype 3) and did not carry the risk factors at chromosome 11 
and 32. 
Five DLA-DRB1, four DLA-DQA1 and four DLA-DQB1 alleles forming a 
total of five different haplotypes was observed in the Scandinavian NSDTR 
population.  In  the  US  and  Canada  the  same  number  of  alleles  have  been 
detected forming a total of seven different haplotypes (Hughes et al., 2010). 
The  two  extra  haplotypes  identified  only  differ  in  DQB1  (DLA-
DRB1*01501/DQA1*00601/DQB1*02301  and  DLA-DRB1*01502/ 
DQA1*00601/DQB1*00301 (Hughes et al., 2010) compared to the haplotypes 
previously identified in the Scandinavian population (Paper I) suggesting that a 
recombination  event  has  occurred  in  the  North  American  population  of 
NSDTR. 
A similar haplotype to the ANA
S-positive risk, where the DLA-DQB1 allele 
differs (DLA-DRB1*00601/DQA1*005011/DQB1*00701), has been shown to 
predispose to another immune-mediated disease, immune-mediated hemolytic 
anemia in a number of different breeds (Kennedy et al., 2006a). This DLA-
DRB1*00601 allele contains the five amino acid epitope RARAA known as 
the shared epitope for rheumatoid arthritis in human (Gregersen et al., 1987). 
Dogs affected by rheumatoid arthritis have an increased risk for developing 
disease when displaying the RARAA epitope from various DLA-DRB1 alleles 
(Ollier et al., 2001). In human SLE patients, a similar epitope as the RA-shared 
epitope (QARAA) is found to be associated with SLE (Tsuchiya et al., 2001).  
The identification of MHC class II as genetic risk factor provides further 
support  that  IMRD  is  an  autoimmune  disease  and  that  it  represents  an   46 
important model for human systemic rheumatic autoimmune diseases, like SLE 
since MHC class II is involved also as a risk factor for development of human 
SLE (Smerdel-Ramoya et al., 2005; Graham et al., 2002). 
The general homozygous disadvantage observed may be due to competitive 
binding actions of MHC class II molecules, but homozygosity at DLA by itself 
is not sufficient to disease development. 
3.3.2  Additional loci identified genetically 
In Paper II, we demonstrated the power of mapping a complex disease in the 
dog by using less than 100 cases and 100 controls, which was the first complex 
disease mapped in the dog. Five candidate loci were identified (four for IMRD, 
one for SRMA and one shared locus). Three of these were strongly validated 
by  fine-mapping  in  IMRD  dogs  (CFA  3,  11  and  24)  and  CFA  32  were 
validated both as separate risk factors for the diseases and combined. We also 
showed  that  ANA-positive  dogs  with  a  speckled  phenotype  (ANA
S)  are 
associated  to  the  loci  in  CFA  11  and  32  and  that  all  ANA-positive  dogs, 
regardless of ANA phenotype are associated to CFA 3 and 24.  
Haplotypes are extended over more than Mb lengths within a dog breed and 
in order to break down the long haplotypes, an additional breed with the same 
phenotype  is  used  (Karlsson  &  Lindblad-Toh,  2008).  This  is  however  a 
challenge  when  using  the  NSDTR,  because  to  our  knowledge,  no  related 
breeds share such a strong predisposition for the SLE-related disease complex, 
which makes it difficult to identify the causative mutation and shorten down 
the long haplotype blocks. A closely related breed could instead be used to 
break down long associated haplotypes by identifying shared non-risk loci. 
The region on CFA 11 contains the PTPN3 gene only and the region on 
CFA  32  is  large  (1.3  Mb in size), spanning several genes. However,  three 
excellent candidate genes occur on the CFA 32 region, DAPP1, PPP3CA and 
BANK1,  of  which  BANK1  has  already  been  associated  with  human  SLE 
(Kozyrev et al., 2008).  
A multi locus analysis was performed to determine whether ANA
S cases 
homozygous for the risk MHC class II in general also carried more risk loci at 
the other identified chromosomes (CFA 11 and 32). There was a trend towards 
an accumulation of risk haplotypes in cases vs. controls (28.3% and 19.4%). 
Since  sample  material  is  small,  no  statistically  significant  results  were 
obtained, however, an accumulation towards more risk genotypes in total is 
observed in ANA
S dogs compared to controls. This supports the finding that 
these three loci jointly contribute to the disease risk and that all loci should be 
taken into account and not only MHC class II. This implicates a multifactorial   47 
disease with incomplete penetrance where environmental triggers are likely to 
play a crucial role. 
Further  analyses  are  needed  to  explore  whether  the  dogs  that  carry  risk 
alleles at all three loci develop a more severe form of disease than dogs only 
carrying risk alleles at a few of the loci. Further studies are also required to 
understand how risk factors interact with unknown environmental risk factors 
for this immune-mediated disease complex. This study has, however, provided 
insight to potential multi-locus contributions to IMRD development.  
3.3.3  A novel pathway suggested 
Gene  expression  studies  correlated  to  genetic  association  to  ANA
S  dogs 
revealed that the PTPN3 (protein tyrosine phosphatase nonreceptor 3) gene on 
CFA 11 is downregulated in dogs with the risk haplotype. This gene belongs to 
the same family as PTPN22, which is a major genetic risk factor for many 
different autoimmune diseases including SLE (Chung & Criswell, 2007). 
It has been suggested that the phosphatase encoded by the PTPN3 gene 
participate in TCR-signaling as a negative regulator by dephosphorylating the 
TCR, which downstream inhibits activation of nuclear factor of activated T-
cells (NF-AT) (Sozio et al., 2004; Han et al., 2000).  
The  CFA  32  region  contains  several  genes  whose  mRNA  levels  are 
upregulated  in  dogs  carrying  the  risk  haplotype.  Because  of  the  canine 
distemper  virus  outbreak  (CDV)  that  occurred  in  the  beginning  of  1900s 
(Strang & MacMillan, 1996), there might have been a selection for this whole 
region  in  dogs  that  survived  the  CDV  outbreaks,  since  this  region  contain 
several genes important for immune function and regulation.  
The  top  SNP  from  the  genotyping  (32:24556037)  correlates  with 
differential mRNA expression of DDIT4L and BANK1. The function of the 
protein  encoded  by  DDIT4L  (DNA-damage-inducible  transcript  4-like)  is 
relatively  unknown  but  it  may  be  involved  in  negative  regulation  of 
mammalian target of rapamycin pathway (mTOR), which has a fundamental 
role in cell growth control (Corradetti et al., 2005). 
BANK1 (B-cell scaffold protein with ankyrin repeats) is an interesting gene 
extensively studied in human SLE. BANK1 was found to be associated to SLE-
development in several independent case-control data sets (Yang et al., 2010; 
Chang et al., 2009; Gateva et al., 2009; Guo et al., 2009; Kozyrev et al., 2008).  
A  modest  upregulation  was  identified  for  DAPP1  and  PPP3CA  mRNA 
expression  in  ANA
S–positive  dogs.  These  genes  encode  proteins  that  are 
essential  for  both  TCR-  and  B-cell  receptor  (BCR)-mediated  immune 
responses and cell proliferation and may act via the NF-AT pathway.   48 
DAPP1  (dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-
phosphoinositide) is expressed in both T- and B-cells (Sommers et al., 2008) 
and  indirectly  inhibit  both  TCR-  and  BCR-signaling  (Ortner  et  al.,  2011). 
Consequently,  it  is  plausible  that  they  may  influence  activation  of  NF-AT 
(Marshall et al., 2000). 
PPP3CA (protein phosphatase 3, catalytic subunit, alpha isozyme) encodes 
the catalytic subunit of calcineurin. This gene is an important and recognized 
target of two important immunosuppressive drugs (cyclosporine A and FK506) 
(Guerini,  1997;  Clipstone  &  Crabtree,  1992)  and  has  been  reported  to  be 
differentially expressed in patients with SLE (Kyttaris et al., 2007). 
NF-AT  proteins  constitute  a  family  of  transcription  factors  with  a  key 
regulatory function of immunological tolerance and can cause development of 
autoimmune  diseases  if  they  are  regulated  incorrectly.  The  NF-AT  family 
consists of five members NFATc1, NFATc2, NFATc3, NFATc4, and NFAT5. 
NFATc1 through NFATc4 are regulated by calcium signaling by calcineurin 
(Serfling et al., 2006). Several of our associated genes show correlation to the 
NF-AT pathway. Importantly, several of the identified genetic risk factors are 
crucial  for  T-cell  activation,  B-cell  activation  and  professional  antigen-
presenting cells like macrophages. It is thus conceivable that patients with a 
more  severe  form  of  IMRD  carry  multiple  of  these  genetic  risk  factors  or 
particular  disadvantageous  combinations  of  risk  factors.  Our  findings  also 
implicate that the NF-AT pathway may be a critical pathway for IMRD. Future 
studies may reveal a possibility for NF-AT involvement also in a sub-type of 
human SLE.  
3.3.4  Same disease complex or not? 
When  this  study  was  initiated  it  was  unclear  whether  IMRD  and  SRMA 
belongs to the same disease complex or not. Firstly, we showed that DLA class 
II  is  only  a  risk  factor  for  IMRD  but  not  SRMA  (Paper  I).  Secondly,  we 
identified a shared genetic risk locus on CFA 32 between the diseases and 
additional  three  that  were  specific  for  IMRD  (Paper  II).  Based  on  our 
investigation, it is clear that there is one common genetic risk locus (CFA 32) 
and  a  number  of  different  genes  involved  as  specific  risk  factors  for  the 
different  diseases.  All  of  the  identified  risk  loci  contain  genes,  which  are 
known to be important for immune function and in particular for the NF-AT 
pathway. It is therefore clear that it is not the same disease, but still unclear if 
the diseases belong to the same complex or whether they should be considered 
as largely different diseases. 
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4  Conclusions 
The  results  of  this  thesis  contribute  to  an  overall  increased  knowledge 
concerning the genetic background for the development of canine SLE-related 
disease. It also highlights the dog as an excellent model organism for mapping 
genetic risk factors for complex traits as the deeper understanding obtained 
might be of major importance for human rheumatic disease as well. The main 
conclusions were as follows: 
 
￘  DLA class II is associated with the canine SLE-related disease IMRD but 
not with SRMA. More specifically, homozygosity for a specific DLA class 
II  haplotype  confers  increased  risk  for  dogs  with  IMRD  with  ANA
S 
phenotype, whereas a general homozygosity at DLA class II gives ANA
H 
dogs an increased risk for developing disease. 
 
￘  Genome-wide association mapping followed by fine-mapping and regional 
re-sequencing identified five additional risk loci for the SLE-related IMRD 
(CFA 3, 8, 11, 24 and 32). The loci on CFA 3, 11 and 32 were associated 
with ANA-positive dogs and the locus on 32 was shared between the two 
phenotypes.  
 
￘  Most ANA
S dogs homozygous for the DLA risk haplotype also carried the 
genetic risk factors at CFA 11 and 32. 
 
￘  mRNA  expression  studies  revealed  that  the  PTPN3  gene  (CFA  11)  is 
significantly  downregulated  and  that  DDIT4L  and  BANK1  mRNA 
expression (CFA 32) is significantly upregulated. 
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￘  Several of the identified genetic risk factors are crucial for T-cell activation, 
B-cell  activation  and  professional  antigen-presenting  cells  like 
macrophages.   51 
5  Future prospects 
5.1  DLA class II 
The  degree  of  LD  in  the  MHC  class  II  region  needs  to  be  defined  in  the 
NSDTR population. It cannot be ruled out that other genes in close proximity 
to  this  region  are  of  importance  for  IMRD  development.  However,  as 
previously  described,  many  other  studies  of  autoimmune  diseases  in  both 
human and animals indicate that MHC class II is directly involved as a major 
genetic risk factor for such diseases. 
The autoantigens that bind to the MHC class II molecules expressed from 
the  risk  haplotype  remains  to  be  defined.  Functional  studies  remain  to 
determine  whether  MHC  class  II  molecules  observed  in  dog  patients  with 
autoimmune  rheumatic  diseases  present  a  common  autoantigen  that  binds 
MHC class II molecules containing the RA epitope. 
5.2  Identification of mutations and downstream targets 
Further genetic studies are needed, especially to explore the ANA
H phenotype 
and shared risk loci for all ANA dogs (regardless of staining). The associated 
regions  on  CFA  3  and  24  seem  to  belong  to  all  ANA  dogs  (regardless  of 
staining), but due to a low sample number in ANA
H dogs, it is possible that we 
have missed to detect separate risk factors for this phenotype. A study using 
more dogs should be conducted. 
One of the highest priority aims is to identify the exact disease-causing 
mutations. Because the mutations could be either coding or regulatory they will 
have  different  functional  consequences  and  accordingly  different  functional 
studies will be needed to define their consequences and involvement in disease 
development. They can be coding (synonymous or non-synonymous), affect 
RNA stability, be located in a promoter or enhancer region, in a conserved   52 
element or in transcription factor binding sites. Different techniques are needed 
depending on the nature of identified mutations. If identified mutations occur 
in  a  coding  region,  the  functional  effect  will  be  studied  using  cell  culture 
methods  by  overexpressing  the  genes  with  the  mutation  and  study  the 
functional consequences. Regulatory mutations can be studied by quantitative 
PCR  (to  evaluate  the  expression)  and  allele-specific  PCR.  Mutations  in 
promoter and enhancer regions can be evaluated for functional consequence on 
transcription using transient transfections in relevant cell culture systems with 
reporters carrying either the wild-type or mutated regulatory regions. 
Pathway  analysis  is  another  informative  way  to  study  the  downstream 
effects of mutations. We are currently collecting fresh PBMC from healthy 
dogs and dogs in the acute phase of the disease, before treatment is started, to 
perform mRNA pathway studies. The goal is to identify downstream targets by 
RNA sequencing (RNAseq). We also aim to sort PBMC and perform RNAseq 
in different cell types (such as B-cells, Th1 and Th2 cells and dendritic cells) to 
evaluate if certain cell types have differentially expressed genes.  
We have shown that  interactions between three loci occur in the ANA
S 
phenotype.  It  would  therefore  be  interesting  to  elucidate  these  three 
interactions in a cell model and study the mechanisms of e.g. NF-AT and T-
cell activation. 
5.3  Characterize the ANA autoantigen and cytokine changes 
Canine  ANA  specificity  determination  is  currently  usually  restricted  to  a 
speckled (non-chromosomal) or homogenous (chromosomal) staining pattern. 
A future goal is to identify subgroups of ANA-reactivity by identifying specific 
autoantigens. A novel autoantigen can be used as a biomarker in diagnostic 
procedures and also help us to further understand the disease mechanism by 
correlating it to genetic studies.  
An imbalance in cytokine production and cytokine levels relates with SLE 
development in humans (Su et al., 2012; Lee et al., 2010). Identification of 
cytokines and possible alterations will therefore be examined in blood samples 
from NSDTRs with immune-mediated diseases. The ultimate ambition is to 
improve treatment and help breeding of healthier dogs in general and Nova 
Scotia duck tolling retrievers in particular.   53 
5.4  Genes and pathways identified in dogs in human SLE 
patients 
Our plan is to study the genes and pathways found in the canine SLE-related 
disease, in a cohort of human SLE patients divided into sub-phenotypes. We 
have designed two arrays, a smaller and a larger. The smaller array is 5.7 Mb 
and covers the genes identified in our dog candidate regions, NF-AT pathway 
and other known “SLE-genes” of interest. The larger array covers 29.4 Mb and 
consists  of  1300  genes  important  for  our  different  dog-immune  projects, 
including diabetes, Addison’s disease, Shar-Pei fever, Lymphocytic thyroiditis, 
and  atopic  dermatitis.  Specific  genes  involved  in  the  NF-AT  pathway, 
autoimmunity  in  general,  T-cell  activation,  B-cell  activation,  interferons, 
interleukins, tumor necrosis factors, toll-like receptors, genes in the hyaluronic 
pathway and the complement system are covered. Both designs capture ± 2 Kb 
relative of identified transcription start sites, ± 20 bp of exon borders and 3’ 
UTR, and all conserved elements located ±100 Kb upstream and downstream 
of the genes and within the gene.  
A  pilot  trial  was  performed  using  the  smaller  array  and  a  total  of  124 
patients and 17 controls. Patients were divided into nine different pools (11-17 
individuals/pool) depending on their clinical or immunological sub-phenotype 
and  analyzed  accordingly.  We  selected  distinctive  patient  groups  (such  as 
patients  with  nephritis,  skin  manifestations  or  presence  of  anti-dsDNA 
antibodies) and tested if rare or common gene variants or pathways occur more 
frequently in specific subgroups. A large phenotypic diversity occurs in human 
SLE patients and it would therefore be helpful to sub-categorize SLE patients. 
We have identified NF-AT as a new major pathway for the canine SLE-like 
disease and this pathway may also play a role in the development of SLE or 
other rheumatoid human diseases.  
The pools had an average coverage of 3775 X and less than 0.3% of the 
tiled  region  missed  sequence  data.  We  identified  a  large  number  of  novel 
SNPs, with many variations that only occurred in the case pools, suggesting 
that these might represent novel genes important for specific phenotypes of 
SLE. However, data need to be confirmed in a larger sample cohort as well as 
SNP genotyping as this pilot trial only gives us a hint of novel pathways and 
genes.  
The ultimate goal is to develop new diagnostic and treatment regimes for 
patients  based  on  identification  of  new  important  genetic  risk  factors  by 
subdividing patients based on both different clinical and genetic appearances.  
     54 
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